Skip to main content

Advertisement

Table 1 Patient and disease characteristics

From: Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy

Characteristic N (%) Characteristic N (%)
Age (years)   ER/PR status 81 (100)
Mean (SD) 65.6 (10.58) ER-positive 80 (98.77)
Median (range) 66 (36–82) ER-negative 1 (1.23)
   PR-positive 51 (62.96)
Stage at diagnosis   PR-negative 4 (4.94)
Stage 1 36 (44.44) PR-unknown 26 (32.10)
Stage 2 45 (55.56)   
   HER2 status  
   HER2-positive
Histology   HER2-negative 81 (100)
Ductal invasive 36 (44.44)   
Lobular invasive 36 (44.44) Ki67 status (%)  
Others 9 (11.12) Mean (SD) 26.76 (20.44)
   Median (range) 25 (3–90)
Tumor size   Ki67 < 15% 22 (27.16)
≤ 20 mm 34 (41.98) Ki67 ≥ 15% 29 (35.80)
20–30 mm 37 (45.68) Ki67 unknown 30 (37.04)
>  30 mm 9 (11.11)   
Unknown 1 (1.23) uPA (ng/mg of protein)  
   Mean (SD) 4.37 (3.9)
Tumor grade   Median (range) 3 (0.1–18.7)
Grade 1 11 (13.58) uPA ≤ 3 41 (50.62)
Grade 2 67 (82.72) uPA >  3 40 (49.38)
Grade 3 3 (3.70)   
   PAI-1 (ng/mg of protein)  
Nodal status   Mean (SD) 21.47 (18.89)
Node-negative 75 (92.59) Median (range) 16 (0–140)
Node-positive PAI-1 ≤ 14 32 (39.51)
Unknowna 5 (6.17) PAI-1 >  14 49 (60.49)
   uPA and PAI-1 combinations  
   uPA ≤ 3 and PAI-1 ≤ 14 30 (37.04)
   uPA ≤ 3 and PAI-1 >  14 11 (13.58)
   uPA > 3 and PAI-1 ≤ 14 2 (2.47)
   uPA > 3 and PAI-1 > 14 38 (46.91)
  1. aAll clinically node-negative